TherapeuticsMD (TXMD) Other Non-Current Liabilities (2012 - 2026)
TherapeuticsMD's (TXMD) quarterly Other Non-Current Liabilities came in at $873000.0 in Q1 2026, up 9.81% YoY from $795000.0 in Q1 2025, and little changed on a QoQ basis from $873000.0 in Q4 2025.
TherapeuticsMD (TXMD) Other Non-Current Liabilities (2012 - 2026) Analysis & Trends
TherapeuticsMD (TXMD) has 9 years of Other Non-Current Liabilities data on file, last reported at $873000.0 in Q1 2026.
- Quarterly Other Non-Current Liabilities rose 9.81% year-over-year to $873000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $873000.0 (up 9.81% YoY) and the FY2025 annual result came in at $873000.0, up 17.34% from the prior year.
- Other Non-Current Liabilities steadied at $873000.0 in Q1 2026, from $873000.0 in the prior quarter.
- In the past five years, Other Non-Current Liabilities ranged from a high of $1.2 million in Q1 2022 to a low of $554000.0 in Q2 2022.
- A 5-year average of $854764.7 and a median of $832000.0 in 2025 frame the typical range for Other Non-Current Liabilities.
- Annual changes were most pronounced in 2022 — Other Non-Current Liabilities sank 48.25% — and 2023, when it jumped 114.62%.
- Tracing TXMD's Other Non-Current Liabilities over 5 years: stood at $1.1 million in 2022, then plunged by 42.55% to $636000.0 in 2023, then increased by 16.98% to $744000.0 in 2024, then grew by 17.34% to $873000.0 in 2025, then changed by 0.0% to $873000.0 in 2026.
- The last three Other Non-Current Liabilities figures came in at $873000.0 (Q1 2026), $873000.0 (Q4 2025), and $871000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 44.45 Bn | 43.48 Bn | - |
| 2 | Teva Pharmaceutical Industries | 43.59 Bn | 39.94 Bn | 2.15 Bn |
| 3 | Zoetis | 32.51 Bn | 30.84 Bn | 1.05 Bn |
| 4 | Takeda Pharmaceutical | 28.60 Bn | 22.81 Bn | 5.10 Bn |
| 5 | United Therapeutics | 22.04 Bn | 19.38 Bn | 683.80 Mn |
| 6 | Viatris | 19.00 Bn | 18.11 Bn | 1.46 Bn |
| 7 | Neurocrine Biosciences | 15.53 Bn | 15.14 Bn | 935.80 Mn |
| 8 | Elanco Animal Health | 11.99 Bn | 11.46 Bn | 798.00 Mn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.95 Bn | - |
| 10 | TherapeuticsMD | 23.96 Mn | 14.77 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 873,000.00 |
| Mar 31, 2026 | 873,000.00 |
| Dec 31, 2025 | 873,000.00 |
| Sep 30, 2025 | 871,000.00 |
| Jun 30, 2025 | 832,000.00 |
| Mar 31, 2025 | 795,000.00 |
| Dec 31, 2024 | 744,000.00 |
| Sep 30, 2024 | 705,000.00 |
| Jun 30, 2024 | 637,000.00 |
| Mar 31, 2024 | 637,000.00 |
| Dec 31, 2023 | 636,000.00 |
| Sep 30, 2023 | 1.19 Mn |
| Jun 30, 2023 | 1.19 Mn |
| Mar 31, 2023 | 1.11 Mn |
| Dec 31, 2022 | 1.11 Mn |
| Sep 30, 2022 | 554,000.00 |
| Jun 30, 2022 | 554,000.00 |
| Mar 31, 2022 | 1.23 Mn |
| Dec 31, 2021 | 2.14 Mn |
| Sep 30, 2021 | 758,000.00 |